Last reviewed · How we verify
Glycemic Rescue 2
Glycemic Rescue 2 is an investigational agent designed to improve blood glucose control in patients with diabetes through an undisclosed mechanism.
Glycemic Rescue 2 is an investigational agent designed to improve blood glucose control in patients with diabetes through an undisclosed mechanism. Used for Type 2 diabetes mellitus (presumed, based on drug name and phase).
At a glance
| Generic name | Glycemic Rescue 2 |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Without publicly available detailed mechanism information for this Phase 3 investigational drug, the precise molecular target and pathway remain proprietary. The name suggests a focus on glycemic management, likely targeting glucose homeostasis through modulation of insulin secretion, glucose uptake, or hepatic glucose production.
Approved indications
- Type 2 diabetes mellitus (presumed, based on drug name and phase)
Common side effects
Key clinical trials
- Glycemic Targets During CPB in Elderly Diabetes (NA)
- Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes (PHASE4)
- Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004) (PHASE3)
- Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083) (PHASE3)
- A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289) (PHASE3)
- Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes Patients (NA)
- Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002) (PHASE3)
- A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |